Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bellerophon Therapeutics stock

Own Bellerophon Therapeutics stock in just a few minutes.


Fact checked

Bellerophon Therapeutics, Inc is a biotechnology business based in the US. Bellerophon Therapeutics shares (BLPH) are listed on the NASDAQ and all prices are listed in US Dollars. Bellerophon Therapeutics employs 18 staff and has a market cap (total outstanding shares value) of USD$87.5 million.

How to buy shares in Bellerophon Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bellerophon Therapeutics. Find the stock by name or ticker symbol: BLPH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bellerophon Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bellerophon Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bellerophon Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Bellerophon Therapeutics share price

Use our graph to track the performance of BLPH stocks over time.

Bellerophon Therapeutics shares at a glance

Information last updated 2020-10-20.
52-week range USD$0.27 - USD$19.4
50-day moving average USD$9.9769
200-day moving average USD$12.6263
Wall St. target price USD$26.5
PE ratio 5.2941
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.085

Buy Bellerophon Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bellerophon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Bellerophon Therapeutics under- or over-valued?

Valuing Bellerophon Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bellerophon Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bellerophon Therapeutics's P/E ratio

Bellerophon Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Bellerophon Therapeutics shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Bellerophon Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -27.38%
Return on equity TTM -52.9%
Profit margin 0%
Book value $5.622
Market capitalisation USD$87.5 million

TTM: trailing 12 months

Shorting Bellerophon Therapeutics shares

There are currently 205,321 Bellerophon Therapeutics shares held short by investors – that's known as Bellerophon Therapeutics's "short interest". This figure is 17% down from 247,368 last month.

There are a few different ways that this level of interest in shorting Bellerophon Therapeutics shares can be evaluated.

Bellerophon Therapeutics's "short interest ratio" (SIR)

Bellerophon Therapeutics's "short interest ratio" (SIR) is the quantity of Bellerophon Therapeutics shares currently shorted divided by the average quantity of Bellerophon Therapeutics shares traded daily (recently around 52781.748071979). Bellerophon Therapeutics's SIR currently stands at 3.89. In other words for every 100,000 Bellerophon Therapeutics shares traded daily on the market, roughly 3890 shares are currently held short.

However Bellerophon Therapeutics's short interest can also be evaluated against the total number of Bellerophon Therapeutics shares, or, against the total number of tradable Bellerophon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellerophon Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bellerophon Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0273% of the tradable shares (for every 100,000 tradable Bellerophon Therapeutics shares, roughly 27 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellerophon Therapeutics.

Find out more about how you can short Bellerophon Therapeutics stock.

Bellerophon Therapeutics share dividends

We're not expecting Bellerophon Therapeutics to pay a dividend over the next 12 months.

Have Bellerophon Therapeutics's shares ever split?

Bellerophon Therapeutics's shares were split on a 1:15 basis on 10 February 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellerophon Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Bellerophon Therapeutics shares which in turn could have impacted Bellerophon Therapeutics's share price.

Bellerophon Therapeutics share price volatility

Over the last 12 months, Bellerophon Therapeutics's shares have ranged in value from as little as $0.27 up to $19.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellerophon Therapeutics's is -0.4562. This would suggest that Bellerophon Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bellerophon Therapeutics has bucked the trend.

Bellerophon Therapeutics overview

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site